10-Q: QHSLab, Inc. Reports Increased Revenue Driven by Integrated Service Program Growth in Q2 2024
Quarterly Report
QHSLab, Inc. saw a revenue increase in the second quarter of 2024, primarily driven by a significant rise in its Integrated Service Program revenue.
Summary
- QHSLab, Inc. reported its financial results for the quarter ended June 30, 2024, showing a revenue increase compared to the same period in 2023.
- The company's revenue for the quarter was $473,073, up from $404,769 in the prior year, and for the six months ended June 30, 2024, revenue was $961,660 compared to $757,568 in 2023.
- The increase in revenue was primarily due to a 104% increase in Integrated Service Program (ISP) revenue for the quarter and a 154% increase for the six-month period.
- Gross profit for the quarter was $294,445, with a gross margin of 62.2%, compared to $226,828 and 56.0% in the same quarter of the previous year.
- For the six-month period, gross profit was $580,603 with a gross margin of 60.4%, compared to $414,170 and 54.7% in the prior year.
- The company experienced a net loss of $2,890 for the quarter and $21,415 for the six-month period, compared to a net loss of $106,727 and $299,282 for the same periods in 2023.
- The company's cash and cash equivalents were $104,200 as of June 30, 2024, compared to $51,582 at the end of 2023.
- The company has a significant amount of debt, including convertible notes payable of $1,223,500, and is currently in default on some of its debt obligations.
- The company's management has expressed concerns about its ability to continue as a going concern due to its history of losses and high leverage.
Sentiment
Score: 3
Explanation: The document presents a mixed picture with positive revenue growth but significant financial risks and going concern issues. The company's default on debt and ineffective controls contribute to a negative sentiment.
Positives
- The company experienced a significant increase in revenue, particularly from its Integrated Service Program.
- Gross profit margins improved for both the three and six-month periods.
- The company reduced its net loss compared to the same periods in the previous year.
- Cash and cash equivalents increased during the period.
- The company generated positive cash flow from operations during the six-month period.
Negatives
- The company has a history of losses and is highly leveraged.
- The company is in default on some of its debt obligations.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company's disclosure controls and procedures were deemed ineffective.
Risks
- The company's ability to continue as a going concern is dependent on securing additional financing and generating positive cash flow.
- The company is in default on its convertible notes, and lenders could exercise their rights, which would have a material adverse effect on the business.
- The company's working capital requirements are expected to increase, and additional financing may not be available on acceptable terms.
- The company's disclosure controls and procedures are ineffective, which could lead to inaccurate financial reporting.
Future Outlook
The company plans to increase revenues by expanding its physician network, introducing new products, and charging subscription fees for its QHSLab software. The company's ability to operate profitably depends on its ability to generate revenues from its software and product sales.
Management Comments
- Management believes that the information provided is relevant to an assessment and understanding of the company's results of operations and financial condition.
- Management has identified corrective actions for the weakness in disclosure controls and will periodically reevaluate the ability to add personnel and implement improved review procedures.
- Management acknowledges that the company is currently in default of its obligations under the First OID Note and the Second OID Note.
Industry Context
The company operates in the medical device technology and software-as-a-service (SaaS) sector, focusing on value-based healthcare and digital therapeutics. The company's solutions aim to enable primary care physicians to increase their revenues by providing tools for chronic disease management and preventive care. The company is leveraging the trend of increased recognition by regulators and insurers of the benefits of digital medicine technologies for managing chronic conditions.
Comparison to Industry Standards
- QHSLab's focus on providing PCPs with tools to manage chronic diseases aligns with the broader industry trend towards value-based care and digital health solutions.
- The company's revenue growth, particularly in its Integrated Service Program, indicates a positive market response to its offerings.
- However, the company's financial challenges, including its high debt and going concern issues, are not uncommon for early-stage companies in the medical technology sector.
- Compared to established players in the medical device and SaaS space, QHSLab is still in a growth phase and faces significant financial and operational risks.
- Companies like Teladoc Health and Livongo (now part of Teladoc) have demonstrated the potential of digital health solutions, but also highlight the challenges of achieving profitability and sustainable growth in this competitive market.
Related Party Transactions
- Amounts due to related parties consist of cash advances received from the principal shareholder.
- The company has convertible notes payable to a shareholder and Mercer Fund.
Stakeholder Impact
- Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
- Employees may be impacted by the company's financial challenges and potential restructuring.
- Customers (physicians) may be affected by the company's ability to continue providing services and products.
- Creditors face the risk of non-payment due to the company's default on debt obligations.
Next Steps
- The company will continue to upgrade its QHSLab platform to increase the number of products sold.
- The company will seek to expand its customer base and launch additional products.
- The company will explore options to raise additional capital or borrow additional funds.
- The company will implement corrective actions for the weakness in disclosure controls.
Key Dates
| Date | Description |
|---|---|
| 2021-05-07 | Effective date of a Convertible Promissory Note issued to a shareholder. |
| 2021-06-21 | Date of Series A2 Preferred Stock issuance. |
| 2021-06-23 | Date of purchase agreement to acquire assets from MedScience Research Group. |
| 2021-08-10 | Effective date of a Securities Purchase Agreement with an accredited investor. |
| 2021-11-11 | Mercer Fund converted a portion of the principal amount of the $806,000 Note. |
| 2021-12-29 | Date of Series A2 Preferred Stock issuance. |
| 2021-12-30 | Date of Series A2 Preferred Stock issuance. |
| 2022-07-19 | Effective date of a Securities Purchase Agreement with Mercer Fund. |
| 2022-07-26 | Date of a Securities Purchase Agreement with Mercer Fund. |
| 2022-07-27 | Mercer Fund converted a portion of the principal amount of the $806,000 Note. |
| 2023-10-05 | The Company agreed to reduce the conversion price with respect to $10,500 of the amounts payable pursuant to the $806,000 Note. |
| 2024-03-04 | The Company agreed to reduce the conversion price with respect to $12,000 of the amounts payable pursuant to the $806,000 Note. |
| 2024-06-30 | End of the quarterly period covered by the report. |
| 2024-08-14 | Date of the report and the number of common shares outstanding. |
Keywords
QHSLab, Integrated Service Program, AllergiEnd, SaaS, revenue, gross profit, net loss, convertible notes, debt, going concern, medical device, digital therapeutics, healthcare, diagnostics, immunotherapy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.